8 research outputs found
Comparison of Acute and Late Toxicity of Two Regimens of 3- and 5-Week Concomitant Boost Prone IMRT to Standard 6-Week Breast Radiotherapy
Purpose: Limited information is available comparing toxicity of accelerated radiotherapy (RT) to that of standard fractionation RT for early stage breast cancer. We report early and late toxicities of two prone regimens of accelerated intensity-modulated radiation therapy (IMRT) with a concomitant boost (CB) to the tumor bed delivered over 3 or 5âweeks as compared to standard 6âweek RT with a sequential electron boost. Methods: From 2/2003 to 12/2007, 169 consecutive patients with Stage IâII breast cancer were offered the choice to undergo prone RT with either: a 6-week standard RT regimen of 46âGy/23 fractions (fx) to the whole breast (WB), followed by a14 Gy sequential boost (SB) to the tumor bed (6wSB), a 5-week regimen of 50âGy to WB with an IMRT CB of 6.25âGy in 25 fx (5wCB); or a 3-week protocol of 40.5âGy to WB with an IMRT CB of 7.5âGy in 15 fx (3wCB). These regimens were estimated as biologically equivalent, based on alpha/betaâ=â4 for tumor control. Toxicities were reported using RTOG and LENT/SOMA scoring. Results: 51/169 patients chose standard 6wSB, 28 selected 5wCB, and 90 enrolled in 3wCB protocol. Maximum acute toxicity was Grade 3 dermatitis in 4% of the patients in the 6wSB compared 1% in 3wCB. In general, acute complications (breast pain, fatigue, and dermatitis) were significantly less in the 3wCB than in the other schedules (Pâ<â0.05). With a median follow-up of 61âmonths, the only Grade 3 late toxicity was telangiectasia in two patients: one in 3wCB and one in 5wCB group. Notably, fibrosis was comparable among the three groups (Pâ=âNS). Conclusion: These preliminary data suggest that accelerated regimens of breast RT over 3 or 5âweeks in the prone position, with an IMRT tumor bed CB, result in comparable late toxicity to standard fractionation with a sequential tumor boost delivered over 6âweeks. As predicted by radiobiological modeling the shorter regimen was associated with less acute effects
Use of a Flexible Inflatable Multi-Channel Applicator for Vaginal Brachytherapy in the Management of Gynecologic Cancer
Introduction: Evaluate use of novel multi-channel applicator (MC) CapriTM to improve vaginal disease coverage achievable by single-channel applicator (SC) and comparable to Syed plan simulation. Material and Methods: 28 plans were evaluated from 4 patients with primary or recurrent gynecologic cancer in the vagina. Each received whole pelvis radiation, followed by 3 weekly treatments using HDR brachytherapy with a 13-channel MC. Upper vagina was treated to 5 mm depth to 1500 cGy/3 fractions with a simultaneous integrated boost totaling 2100 cGy/3 fractions to tumor. Modeling of SC and Syed plans was performed using MC scans for each patient. Dosimetry for MC and SC plans was evaluated for PTV700 cGy coverage, maximum dose to 2cm3 to bladder, rectum as well as mucosal surface points. Dosimetry for Syed plans was calculated for PTV700 cGy coverage. Patients were followed for treatment response and toxicity.Results: Dosimetric analysis between MC and SC plans demonstrated increased tumor coverage (PTV700 cGy), with decreased rectal, bladder, and contralateral vaginal mucosa dose in favor of MC. These differences were significant (p<0.05). Comparison of MC and Syed plans demonstrated increased tumor coverage in favor of Syed plans which were not significant (p=0.71). Patients treated with MC had no cancer recurrence or â„ grade 3 toxicity.Conclusion: Use of MC was efficacious and safe, providing superior coverage of tumor volumes â€1cm depth compared to SC and comparable to Syed implant. MC avoids excess dose to surrounding organs compared to SC, and potentially less morbidity than Syed implants. For tumors extending â€1cm depth, use of MC represents an alternative to an interstitial implant